title: Effect of matrix metalloproteinase inhibitors on tumor growth and spontaneous metastasis.
abstract: Four potent, synthetic inhibitors of matrix metalloproteinases (MMPs) were assessed as inhibitors of tumor growth and spontaneous metastasis to the lung. Mat Ly Lu rat prostate tumor, LOX human melanoma and M27 murine Lewis lung tumor were implanted subcutaneously (s.c.) in mice and allowed to grow for 3-12 days. The lungs of the tumor-bearing mice were then removed and implanted s.c. into untreated mice, and the outgrowth of secondary tumors from the implanted lungs measured. The incidence and rate of outgrowth of secondary tumors increased with the length of primary tumor growth, validating these measurements as indices of spontaneous metastasis to the lung. Compounds were tested by s.c. implantation of minipumps which delivered compound throughout the period of primary tumor growth and spontaneous metastasis to the lung at steady-state drug concentrations orders of magnitude greater than the concentrations needed to either inhibit collagenase, gelatinase or stromelysin in vitro. Inhibitor treatment slowed the growth of primary s.c. Mat Ly Lu and LOX tumors by 40-60% but had no significant effect on the growth of primary M27 tumors. Surprisingly, inhibitor treatment had no significant effect on the ability of the lung to generate secondary tumors when reimplanted s.c. in untreated mice. Because of the possible importance of cathepsins B, H and L in tumor growth and metastasis, the irreversible inhibitor E-64 was also infused by s.c. minipump. E-64 had no effect on the growth or spontaneous metastasis of Mat Ly Lu or M27 tumors.
authors.affiliation: Department of Pharmacology, Glaxo Inc., Research Triangle Park, NC 27709, USA.
authors.forename: J G
authors.initials: JG
authors.lastname: Conway
authors.forename: S J
authors.initials: SJ
authors.lastname: Trexler
authors.forename: J A
authors.initials: JA
authors.lastname: Wakefield
authors.forename: B E
authors.initials: BE
authors.lastname: Marron
authors.forename: D L
authors.initials: DL
authors.lastname: Emerson
authors.forename: D M
authors.initials: DM
authors.lastname: Bickett
authors.forename: D N
authors.initials: DN
authors.lastname: Deaton
authors.forename: D
authors.initials: D
authors.lastname: Garrison
authors.forename: M
authors.initials: M
authors.lastname: Elder
authors.forename: A
authors.initials: A
authors.lastname: McElroy
authors.forename: N
authors.initials: N
authors.lastname: Willmott
authors.forename: A J
authors.initials: AJ
authors.lastname: Dockerty
authors.forename: G M
authors.initials: GM
authors.lastname: McGeehan
mesh_terms: D000818:Animals; D000970:Antineoplastic Agents / Q000494:pharmacology*; D002455:Cell Division / Q000187:drug effects; D006801:Humans; D008175:Lung Neoplasms / Q000556:secondary; D019278:Matrix Metalloproteinase 3; D061965:Matrix Metalloproteinase Inhibitors; D008666:Metalloendopeptidases / Q000037:antagonists & inhibitors*; D051379:Mice; D009362:Neoplasm Metastasis; D009368:Neoplasm Transplantation; D011480:Protease Inhibitors / Q000494:pharmacology*; D051381:Rats; D014407:Tumor Cells, Cultured / Q000201:enzymology* / Q000473:pathology
chemical_list: D000970:Antineoplastic Agents; D061965:Matrix Metalloproteinase Inhibitors; D011480:Protease Inhibitors; D008666:Metalloendopeptidases; D019278:Matrix Metalloproteinase 3